<info type="ChemicalEntity">rTMS</info> of <info type="GeneOrGeneProduct">supplementary motor area</info> modulates therapy-induced <info type="DiseaseOrPhenotypicFeature">dyskinesias</info> in <info type="DiseaseOrPhenotypicFeature">Parkinson disease</info>.

The neural mechanisms and circuitry involved in <info type="DiseaseOrPhenotypicFeature">levodopa-induced dyskinesia</info> are unclear. Using <info type="ChemicalEntity">repetitive transcranial magnetic stimulation</info> (<info type="ChemicalEntity">rTMS</info>) over the <info type="GeneOrGeneProduct">supplementary motor area</info> (<info type="GeneOrGeneProduct">SMA</info>) in a group of patients with advanced <info type="DiseaseOrPhenotypicFeature">Parkinson disease</info>, the authors investigated whether modulation of <info type="GeneOrGeneProduct">SMA</info> excitability may result in a modification of a <info type="DiseaseOrPhenotypicFeature">dyskinetic state</info> induced by continuous <info type="ChemicalEntity">apomorphine</info> infusion. <info type="ChemicalEntity">rTMS</info> at <info type="ChemicalEntity">1 Hz</info> was observed to markedly reduce drug-induced <info type="DiseaseOrPhenotypicFeature">dyskinesias</info>, whereas <info type="ChemicalEntity">5-Hz rTMS</info> induced a slight but not significant increase.